Month: March 2025

2024 Full-year revenues increased by 5.2% year over year, reaching a record-breaking $2.76 billion, while net income grew by 24.5% to a record-breaking $79.7 million OR YEHUDA, Israel, March 20, 2025 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (Nasdaq and TASE: FORTY) (“Formula” or the “Company”), a global information technology group engaged, through its subsidiaries and affiliates, in providing software consulting services and computer-based business solutions and developing proprietary software products, today announced its fourth quarter and full year 2024 results of operations. Financial Highlights for the Fourth Quarter Ended December 31, 2024  ● Revenues for the fourth quarter ended December 31, 2024, increased by 8.0% year over year, reaching a fourth quarter record-breaking $691.5 million, compared to $640.3 million...

Fourth Quarter Comparable Sales Declined (3.0)%: a +190 Basis Point Improvement vs. Third Quarter 2024 Fourth Quarter Diluted GAAP EPS of $1.89: Above the Midpoint of Updated Guidance Provided Company Announces Launch of Jordan Brand in 145 Stores and Online Beginning in Late April Quarterly Dividend Increased by 18% Per Share KATY, Texas, March 20, 2025 (GLOBE NEWSWIRE) — Academy Sports and Outdoors, Inc. (Nasdaq: ASO) (“Academy” or the “Company”) today announced its financial results for the fourth quarter and fiscal year ended February 1, 2025. Fourth quarter and fiscal year 2024 included 13 and 52 weeks, respectively, compared to 14 and 53 weeks in fourth quarter and fiscal year 2023, respectively. “Looking back on 2024, our team made significant strides toward achieving our long-term goals, all while...

Conference call will be held today, Thursday, March 20 at 9:00 am ET CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024. 4Q24 Financial highlightsRevenues increased 43% to $761 thousand in 4Q24 compared to $531 thousand in 4Q23. Operating loss improved by 10% compared to the fourth quarter of 2023. Cash balance was $3.7 million as of December 31, 2024.Recent Operational HighlightsExpanded total covered lives to approximately 51 million compared to 4 million as of December 31 2023. Received a new Current Procedural Terminology...

FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025 Launch preparations on track toward goal to treat first patient in 3Q 2025 CLEVELAND, March 20, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2024, and announced progress in the ongoing review with the U.S. Food and Drug Administration (FDA) regarding prademagene zamikeracel (pz-cel) and plans for the U.S. commercial launch of pz-cel for recessive dystrophic epidermolysis bullosa (RDEB), if approved. The Company will host a conference call and webcast today at 8:30 a.m. ET. “The RDEB community continues to highlight the unmet medical need for new therapies that could provide long-lasting healing and pain...

Reports record-high revenues since inception MONTREAL, March 20, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2024. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2024 Highlights Financial resultsRevenues were $371,304, an increase of $43,105 or 13% over the prior year. The increase was driven by the growth of our key promoted products, the impact of hyperinflation in Argentina, partly offset by declines of our mature products and the depreciation of select LATAM currencies. Gross margin was $174,405 or 47% of revenues compared to $152,652 or 47%...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025 Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904, with topline data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025 Multiple data presentations at AAD 2025 highlighting the potential of vilobelimab in reducing systemic inflammation Cash, cash equivalents and marketable securities of €55.2 million as of December 31, 2024 Additional €28.7 million ($30.0 million) in gross proceeds subsequently raised by an underwritten public offering...

Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million 2024 year-end cash and cash equivalents of $69.3 million Continues to target near-term (by end of 1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of manufacturing expenses Company announced in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA against LP.8.1, KP.3.1.1, and XEC, comprising the majority of SARS-CoV-2 variants currently circulating in the U.S, reinforcing the durability of PEMGARDA’s neutralizing activity shown amid viral evolution Company announced positive Phase 1 clinical data for next-generation...

A Pivotal Year, Marking Accomplishment of Strategic Shift to Data Collection, Hits Milestones Toward Becoming a Driving Force in the AI Revolution 2024 revenue increased to $31.8 million, of which $7.4 million was in the fourth quarter;2024 net profit rose to $5.8 million and adjusted EBITDA reached $9.4 million; Cash and liquid investments balance at year-end amounted to $25 million TEL AVIV, Israel, March 20, 2025 (GLOBE NEWSWIRE) — Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of web data collection solutions, today announced financial results for the fourth quarter and full year ended December 31, 2024. Shachar Daniel, Chief Executive Officer of Alarum, said: “2024 was a landmark year for Alarum, as we successfully executed our strategic vision, to focus on data collection. This...

Duke Robotics’ successful transition from development to commercialization, highlighted by a service agreement with the Israel Electric Corporation, strategic European expansion with the establishment of Greek subsidiary, as the company eyes fast growing civilian utility maintenance market with its innovative drone technologies FORT LAUDERDALE, FL, March 20, 2025 (GLOBE NEWSWIRE) — Duke Robotics Corp. (OTCQB: DUKR) (“Duke Robotics” or the “Company”), a leader in advanced robotics technology and autonomous drone solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. Yossef Balucka, Chief Executive Officer of Duke Robotics, commented: “2024 was a transformative year for Duke Robotics, marked by our successful transition...